Skip to main content
Clinical Trials/NCT02877953
NCT02877953
Unknown
N/A

Transitional Care Interventions Post-TIPS

Shihezi University0 sites76 target enrollmentJanuary 2013
ConditionsFibrosis

Overview

Phase
N/A
Intervention
Not specified
Conditions
Fibrosis
Sponsor
Shihezi University
Enrollment
76
Primary Endpoint
The compliance behavior associated with complications post-TIPS
Last Updated
9 years ago

Overview

Brief Summary

The investigators conducted a randomized controlled trial to describe if multidisciplinary and patient-centered transitional care interventions for patients with cirrhosis post-TIPS can improve compliance behavior and reduce complications post-TIPS after discharge.

Registry
clinicaltrials.gov
Start Date
January 2013
End Date
September 2015
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Shihezi University
Responsible Party
Principal Investigator
Principal Investigator

HOU Wei-wei

Director

Shihezi University

Eligibility Criteria

Inclusion Criteria

  • Clinical diagnosis of diagnosis of cirrhosis;
  • Child-Pugh Score \<10;
  • Informed Consent.

Exclusion Criteria

  • Age \<18 years;
  • Right ventricular failure;
  • Severe systemic infection;
  • Hepatocellular carcinoma (HCC);
  • Terminal disease; and
  • Failure to provide written consent to participate in the study.

Outcomes

Primary Outcomes

The compliance behavior associated with complications post-TIPS

Time Frame: 1 and 3 months after discharge

It was surveyed using a self-designed questionnaire based on evidence. The questionnaire includes 6 items that address taking medicine on time, quality low-protein diet intake, going to sleep at a regular time, moderate exercise, emotion regulation, regular follow-up. Item responses are on a 4-point scale (0 = never to 3 = always). Data were collected by face-to-face interviews with trained transition nurses. Change is being assessed

Secondary Outcomes

  • Child-Pugh scores(Baseline, 1 and 3 months after discharge)
  • Blood ammonia levels(Baseline, 1 and 3 months after discharge)
  • incidence of adverse events (shunt dysfunction and hepatic encephalopathy)(1 and 3 months after discharge)

Similar Trials